Safety Study With the Antibody, cG250, and Isotope, 124-Iodine, to Diagnose Patients With Renal Masses.

Inclusion Criteria

• Presence of a renal mass.
• Scheduled for surgical resection of renal mass.
• Expected survival of at least 3 months.
• Karnofsky performance scale ≥70.
• The following laboratory results should be within the following limits within the last 4 weeks prior to study day 1:
• Absolute neutrophil count (ANC) ≥ 1.5 x 10E9/L
• Platelet count ≥ 100 x 10E9/L
• Serum bilirubin ≤ 2.0 mg/dL
• Aspartate aminotransferase (AST) ≤ 2.5 x upper limit of normal (ULN)
• Alanine aminotransferase (ALT) ≤ 2.5 x ULN
• Serum creatinine ≤ 2.0 mg/dL
• Pregnancy Test to be performed on female patients of childbearing potential within 24-48 hours before administration of radioactive material.
• Recovered from toxicity of any prior therapy.
• Able and willing to give valid written informed consent.

Exclusion Criteria

• Intercurrent medical condition that may limit the amount of antibody to be administered.
• Intercurrent medical condition that renders the patient ineligible for surgery.
• New York Heart Association Class III/IV cardiac disease.
• History of autoimmune hepatitis.
• Chemotherapy, radiotherapy, or immunotherapy within 4 weeks prior to the first cG250 dose.
• Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the study.
• Lack of availability for immunological and clinical follow-up assessments.
• Participation in any other clinical trial involving another investigational agent within 4 weeks prior to enrollment.
• Women who are pregnant or breastfeeding.
• Allergy to iodine.